Compare KFY & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | LGND |
|---|---|---|
| Founded | 1969 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 1998 | N/A |
| Metric | KFY | LGND |
|---|---|---|
| Price | $78.81 | $295.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $73.00 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 745.6K | 489.9K |
| Earning Date | 06-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 13.48 | N/A |
| EPS | ★ 5.22 | N/A |
| Revenue | ★ $1,819,519,000.00 | N/A |
| Revenue This Year | $6.92 | $1.25 |
| Revenue Next Year | $3.25 | $19.41 |
| P/E Ratio | ★ $15.09 | $76.27 |
| Revenue Growth | ★ 12.20 | N/A |
| 52 Week Low | $58.27 | $131.67 |
| 52 Week High | $79.19 | $326.63 |
| Indicator | KFY | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 55.19 |
| Support Level | $66.54 | $180.85 |
| Resistance Level | N/A | $326.63 |
| Average True Range (ATR) | 2.27 | 11.83 |
| MACD | 0.64 | -4.15 |
| Stochastic Oscillator | 95.85 | 26.14 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.